New combo aims to beat bladder cancer without bladder removal

NCT ID NCT06571708

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether adding an experimental drug (fianlimab) to standard chemotherapy plus immunotherapy can help people with muscle-invasive bladder cancer avoid bladder removal. About 36 adults will receive either the standard combo or the standard plus fianlimab. The main goal is to see if the cancer disappears after 4 cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gemcitabine, cisplatin, cemiplimab, and fianlimab
What this could lead to
If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life.
What could go wrong
This is a small, early-phase trial (36 people) and may not work for everyone. Side effects from chemotherapy and immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center/ New York Presbyterian Hospital

    RECRUITING

    New York, New York, 10032, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.